Breakthrough chemotherapy-induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of Japan (Q39137612)

9 September 2017

title

Breakthrough chemotherapy-induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of Japan (English)

1 reference

9 September 2017

10

Yoshihiko Maehara

1 reference

9 September 2017

5

Toshiharu Kamura

1 reference

9 September 2017

7

Kazuhiro Yoshida

1 reference

9 September 2017

Kazuo Tamura

1

1 reference

9 September 2017

Keisuke Aiba

2

1 reference

9 September 2017

Toshiaki Saeki

3

1 reference

9 September 2017

Yoichi Nakanishi

4

1 reference

9 September 2017

Hideo Baba

6

1 reference

9 September 2017

Nobuyuki Yamamoto

8

1 reference

9 September 2017

Yuko Kitagawa

9

1 reference

9 September 2017

Mototsugu Shimokawa

11

1 reference

9 September 2017

Koichi Hirata

12

1 reference

9 September 2017

Masaki Kitajima

13

1 reference

9 September 2017

CINV Study Group of Japan

14

1 reference

9 September 2017

publication date

1 December 2016

1 reference

International Journal of Clinical Oncology

9 September 2017

published in

1 reference

9 September 2017

volume

22

1 reference

9 September 2017

issue

2

1 reference

9 September 2017

page(s)

405-412

1 reference

Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan

9 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S10147-016-1069-7

Changing patient perceptions of the side effects of cancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10147-016-1069-7

Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10147-016-1069-7

Antiemetics: American Society of Clinical Oncology clinical practice guideline update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10147-016-1069-7

On the receiving end--patient perception of the side-effects of cancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10147-016-1069-7

Systematic review of the efficacy of antiemetics in the treatment of nausea in patients with far-advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10147-016-1069-7

Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10147-016-1069-7

Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10147-016-1069-7

Safety and pharmacokinetic evaluation of repeated intravenous administration of palonosetron 0.75 mg in patients receiving highly or moderately emetogenic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10147-016-1069-7

The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10147-016-1069-7

Efficacy of Olanzapine Combined Therapy for Patients Receiving Highly Emetogenic Chemotherapy Resistant to Standard Antiemetic Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10147-016-1069-7

Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10147-016-1069-7

Incidence of chemotherapy-induced nausea and emesis after modern antiemetics

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27909835

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10147-016-1069-7

1 reference

9 September 2017

1 reference